MEDIVIR’S FINANCIAL STATEMENT 1 January – 31 December 2005

• Milestone payment received from Tibotec • CD designated on hepatitis C project with Tibotec • Decision to start phase III studies on ME-609 in-house • Decision to focus operations and incorporate subsidiary Medivir HIV Franchise AB • Rights to valomaciclovir (MIV-606) revert to Medivir • Phase IIa study on MIV-210 (HIV) begin • CD, MIV-701, designated on Cathepsin K program • Boehringer Ingelheim return MIV-310 (HIV) • Consolidated net sales were SEK 102.6 (82.6) m. • The loss after tax was SEK -104.7 (-111.5) m; earnings per share were SEK -8.10 (-10.38).

FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Three-month Interim Report will be published on 26 April 2006 The Annual General Meeting will be on 26 April 2006, from 3 p.m. The Six-month Interim Report will be published on 10 July 2006 The Nine-month Interim Report will be published on 23 October 2006 Medivir’s Financial reports are available on its website, from these dates under the ‘Investor/Media’ heading. The Annual Report will be uploaded to Medivir’s website at the end of March/early April. A print version will be available on order from the company.

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links